Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Majority of sinus infections are reported to be caused by common cold and viral infections. These infections are classified as chronic and acute based on severity.
The chronic ones are those lasting for more than 3 months. Acute sinusitis get cured within 30 days.
At preliminary stage, sinus infections get diagnosed by physically inspecting characteristics of nasal mucosa, nasal septum’s structure, and presence of polyps.
At times, even imaging procedures like MRI (Magnetic Resonance Imaging), ultrasound, and CT (computed tomography) could be used to gauge the severity.
The commonly prescribed sinus therapeutic drugs include painkillers, corticosteroids, sulfonamides, antibiotics, and antihistamines.
The antibiotics used for treating bacterial infections herein include cephalospotin’s, penicillin, and macrolides.
Prednisone, triamcinolone, fluticasone, and mometastone are amongst the corticosteroids used to treat sinus infections. Sulfa drugs are inclusive of trimethoprim and sulfamethoxazole.
Antibiotics are expected to witness exponentiation in the forecast period. This could be attributed to diagnostic technologies being developed post introducing rapid microbial tests.
Besides, market players are looking for expansion in the markets of Asia-Pacific like Indonesia, Philippines, China, and India. This trend is expected to boost the market during the forecast period.
The other treatment options include bacterial lysates, capsaicin, anti-IL5, anti-IgE, and antifungals
The sinus therapeutic drugs market players are treading the innovative path followed by approvals to table their superiority. These measures are bound to give impetus to the market during the forecast period.
For instance –
Traditionally, the US and Western European countries have remained the most lucrative markets for sinus therapeutic drug manufacturers. The scenario is likely to witness significant change during the forecast period, as many countries in Asia Pacific are offering lucrative opportunities.
The Asia Pacific sinus therapeutics drugs market is likely to grow at the fastest pace in the forecast period, as the players are expanding in this region, and some of them are also reported to shift their base over here.
Moreover, many countries in Asia Pacific have world’s worst air quality, and respiratory disorders have witnessed a rapid spike, with rise in industrialization.
The market players are launching new products to stand out as differentiators. This strategy is being emphasized on, and has kept the users guessing, regarding novelty.
For instance –
The major players in the sinus therapeutic drug market include:
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The global sinus therapeutic drugs market is expected to witness a substantial CAGR of over 4% between 2022 and 2032. The onslaught of Covid-19 has resulted in increase in production of these drugs as it is directly related to disorders in the nasal tract.
The market players, though vying for innovation, should also think more from the inorganic growth perspective. As such, they should be looking forward to go for mergers, acquisitions, partnerships, joint ventures to be able to reach out to a broader audience.
The sinus therapeutic drugs market is likely to secure a CAGR of 4% through 2032.
The sinus therapeutic drugs market size is estimated to cross USD 6.35 Billion by 2032.
The sinus therapeutic drugs market is likely to record a value of USD 4.29 Billion in 2022.
US is likely to lead the sinus therapeutic drugs market.
Explore Therapy Area Insights
View Reports
Sinus Therapeutic Drugs Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
